Accelerated evolution of brain atrophy and "black holes" in MS patients with APOE-epsilon 4

Christian Enzinger1, Stefan Ropele, Stephen Smith

  • 1Department of Neurology, Karl-Franzens University, Graz, Austria.

Annals of Neurology
|March 30, 2004
PubMed

Insights

The APOE-epsilon4 gene variant accelerates brain tissue loss and lesion evolution in multiple sclerosis (MS) patients, indicating more severe disease progression. This finding highlights APOE-epsilon4 as a significant factor in MS pathology.

Area of Science:

  • Neuroimmunology
  • Genetics
  • Radiology

Background:

  • Apolipoprotein E (APOE)-epsilon4 is linked to worse multiple sclerosis (MS) outcomes.
  • Mechanisms remain unclear, but higher "black hole" lesions were observed in APOE-epsilon4 carriers.

Purpose of the Study:

  • To investigate the impact of APOE genotype on longitudinal brain tissue damage in MS.
  • To assess changes in focal (black hole ratio) and global (brain volume change) damage.

Main Methods:

  • 99 MS patients underwent APOE genotyping, clinical exams, and MRI at baseline and after ~2.7 years.
  • Magnetic resonance imaging (MRI) assessed lesion load (LL) and brain volume change (BVC).
  • Calculated black hole ratio (T(1) LL/T(2) LL) x 100.

Main Results:

  • APOE-epsilon4 carriers showed a fivefold higher annual brain volume reduction (-0.65%) compared to non-carriers (-0.13%).
  • The black hole ratio significantly increased in APOE-epsilon4 carriers (5.5% to 12.4%) but remained stable in non-carriers (5.0% to 5.7%).
  • Higher baseline T(2) and T(1) LL were noted in epsilon4 carriers, despite shorter disease duration.

Conclusions:

  • Accelerated brain tissue loss and increased black hole formation in MS patients with APOE-epsilon4 suggest more pronounced tissue destruction.
  • APOE genotype significantly influences the rate and pattern of brain damage in multiple sclerosis.
  • MRI evidence supports APOE-epsilon4 as a marker for more aggressive MS.

Related Concept Videos

Alzheimer Disease l: Introduction01:29

Alzheimer Disease l: Introduction

Alzheimer disease is a chronic, progressive, and irreversible neurodegenerative disorder and the most common cause of dementia in older adults. It leads to gradual neuronal loss, causing cognitive decline, behavioral changes, and loss of functional independence.Risk Factors and EtiologyThe disease is multifactorial. Age is the strongest risk factor, with prevalence doubling every 5 years after age 65. Genetic factors include mutations in genes such as APP, PSEN1, and PSEN2, which are associated...
Alzheimer Disease ll: Pathophysiology01:23

Alzheimer Disease ll: Pathophysiology

Alzheimer disease involves structural changes in the brain that begin long before symptoms appear. The most distinctive features are extracellular neuritic plaques and intracellular neurofibrillary tangles.Neuritic plaques form in the cerebral cortex and around blood vessels. These plaques contain a dense core of beta-amyloid (Aβ)—a toxic protein fragment that clumps outside neurons. The core is surrounded by damaged neuronal extensions, as well as reactive astrocytes and microglia. Abnormal...
Multiple Sclerosis l: Introduction01:19

Multiple Sclerosis l: Introduction

Multiple sclerosis is a chronic autoimmune disease of the central nervous system (CNS) that affects the brain, spinal cord, and optic nerves. It is an inflammatory demyelinating disorder and a leading cause of neurological disability in young adults.EpidemiologyMS commonly begins between 20 and 40 years of age and is twice as common in women. Its exact cause remains unclear, but genetic susceptibility contributes, with higher risk in first-degree relatives and identical twins. A greater...
Alzheimer's Disease: Overview01:26

Alzheimer's Disease: Overview

Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ and tau...